News

PD-1 Inhibitor Drugs Market To Reach USD 201.5 Bn By 2035, Expanding At 15.5% CAGR TMR Analysis

PD-1 Inhibitor Drug PD-1 Inhibitor Drugs Market poised for robust growth, driven by rising cancer therapies and expanding immuno-oncology a ...
HealthDay on MSN4h

High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma

Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) ...
Dermatology Advisor13h

Cancer Vaccine Candidate Narrowly Misses Endpoint in Advanced Melanoma Trial

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.
Zacks Small Cap Research on MSN14h

AEMD: Cohort 2 Enrollment Open; Initial Cohort 1 Data Analysis Expected Next Month

AEMD READ THE FULL AEMD RESEARCH REPORT ENROLLMENT FOR ONCOLOGY TRIAL COHORT 2 HAS COMMENCED Data Safety Monitoring Board Recommended AEMD Progress Trial Without Modification Aethlon Medical ...
The Manila Times15h

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...
Cancer Therapy Advisor23h

IRR Rates May Be Lower Than Expected in the Real World

Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.